Biosynthesis of Nucleoside Diphosphorimidates in *Campylobacter jejuni*

Zane W. Taylor, Haley A. Brown, Hazel M. Holden, and Frank M. Raushel

Department of Biochemistry & Biophysics, Texas A&M University, College Station, Texas 77843, United States

Supporting Information

**ABSTRACT:** *Campylobacter jejuni* is a pathogenic Gram-negative bacterium and a leading cause of food-borne gastroenteritis. *C. jejuni* produces a capsular polysaccharide (CPS) that contains a unique O-methyl phosphoramidate modification (MeOPN). Recently, the first step in the biosynthetic pathway for the assembly of the MeOPN modification to the CPS was elucidated. It was shown that the enzyme Cj1418 catalyzes the phosphorylation of the amide nitrogen of L-glutamine to form L-glutamine phosphate. In this investigation, the metabolic fate of L-glutamine phosphate was determined. The enzyme Cj1416 catalyzes the displacement of pyrophosphate from MgCTP by L-glutamine phosphate to form CDP-L-glutamine. The enzyme Cj1417 subsequently catalyzes the hydrolysis of CDP-L-glutamine to generate cytidine diphosphorimidate and L-glutamate. The structures of the two novel intermediates, CDP-L-glutamine and cytidine diphosphorimidate, were confirmed by 31P nuclear magnetic resonance spectroscopy and mass spectrometry. It is proposed that the enzyme Cj1416 be named CTP:phosphoglutamine cytidyltransferase and that the enzyme Cj1417 be named γ-glutamyl-CDP-amidase hydrolase.

The pathogenic Gram-negative bacterium *Campylobacter jejuni* is a leading cause of food-borne gastroenteritis. While pathogenic to humans, *C. jejuni* is a commensal organism in chickens, and as a result, contaminated poultry serves as a common route of human infection. While most *C. jejuni* infections cause a case of gastroenteritis, approximately 1 in 1000 infections results in the autoimmune disease Guillain-Barré syndrome. Like many other organisms, *C. jejuni* uses a capsular polysaccharide (CPS) to improve fitness. The capsular polysaccharide of *C. jejuni* protects the organism from bacteriophages and shields it from the host immune response. More than 40 different strains of *C. jejuni* have been identified to date, and each strain is believed to produce a unique CPS variant. In *C. jejuni* strain NCTC 11168, a cluster of approximately 35 genes is responsible for the synthesis and export of the CPS. Moreover, *C. jejuni* has evolved the ability to synthesize a unique O-methyl phosphoramidate (MeOPN) modification found on the CPS that improves the pathogenicity of the bacterium and promotes evasion of the host immune response. The structures of the MeOPN modification to the CPS in *C. jejuni* strain NCTC 11168 and hypermotile strain 11168H are illustrated in Scheme 1.

**Scheme 1. Structures of the O-Methyl Phosphoramidate Modifications to the CPS in *C. jejuni***

We have recently shown that the enzyme denoted with the locus tag Cj1418 from *C. jejuni* strain 11168H catalyzes the first committed step in the biosynthesis of the MeOPN. This enzyme, L-glutamine kinase, catalyzes the unprecedented ATP-dependent phosphorylation of the amide nitrogen of L-glutamine (1) to form L-glutamine phosphate (2) as shown in Scheme 2A. However, the subsequent metabolic fate of this novel enzyme intermediate has not been addressed. The primary focus of this investigation is to identify those enzymes that can harness the phosphoramidate moiety contained within L-glutamine phosphate for the ultimate construction of the O-methyl phosphoramidate modification of the CPS.

The two most likely enzymes of unknown function from *C. jejuni* to utilize L-glutamine phosphate as a substrate during the biosynthesis of the O-methyl phosphoramidate modification of the CPS are Cj1417 and Cj1416. Cj1417 is functionally annotated as a Type I amidotransferase from cog2071. Members of the Type I amidotransferase family of enzymes typically catalyze the hydrolysis of L-glutamine or amide-substituted derivatives of this amino acid. Currently, the closest functionally characterized homologue to Cj1417 is the enzyme PuuD (23% identical sequence) from *Escherichia coli*, an enzyme that catalyzes the hydrolysis of 4-(γ-L-glutamylamino)butanoate to 4-aminobutanoate and L-glutamate. Cj1416 is currently annotated as a nucleotidyl...
Scheme 2. Reaction Catalyzed by Cj1418 and the Predicted Functions of Cj1417 and Cj1416

To test our initial prediction that the combination of Cj1416 and Cj1417 catalyzes the formation of a nucleoside diphosphoramidate, these two enzymes were incubated together in the presence of MgCTP and an excess of L-glutamine phosphate (2) at pH 8.0. After 45 min, all of the CTP (retention time of 8.7 min (Figure 1A)) was converted to a new product with a retention time of 5.9 min (Figure 1B). The retention time of the new reaction product formed in the presence of Cj1417 and Cj1416 is identical to that of authentic cytidine diphosphoramidate (Figure 1E).

The identity of the new reaction product as cytidine diphosphoramidate was further supported by the acquisition of the negative ion electrospray ionization (ESI) mass spectrum of the unfractionated reaction mixture upon incubation of MgCTP, L-glutamine phosphate, Cj1417, and Cj1416 at pH 8.0 in ammonium bicarbonate buffer. A peak at m/z 401.03 was observed that is consistent with that expected for cytidine diphosphoramidate (Figure S1). These experiments demonstrate that Cj1417 and Cj1416 use MgCTP and L-glutamine phosphate to catalyze the formation of CDP phosphoramidate, pyrophosphate, and L-glutamate.
In parts B and C of Scheme 2, we have proposed that either phosphoramidate (3) or L-glutamine phosphate (2) is used to displace pyrophosphate from a nucleoside triphosphate to form either a nucleoside diphosphoramidate (4) or NDP-L-glutamine (5) as an intermediate. The reactivity of Cj1416 with each of these potential substrates was tested with MgCTP as the acceptor nucleotide, and the reaction was monitored by ion exchange chromatography at 255 nm. In separate experiments, either phosphoramidate (3) or L-glutamine phosphate (2) was incubated with CTP, MgCl₂, and Cj1416 at pH 8.0 for 45 min. Utilizing the chemically synthesized phosphoramidate (3) as a potential substrate, there was no change in the high-performance liquid chromatography chromatogram when compared to that of CTP alone (Figure 1C). However, when Cj1416 was incubated with L-glutamine phosphate (2) and MgCl₂, all of the CTP was converted to a new product that corresponds to a molecule with a net charge of approximately −2 (Figure 1D). This result demonstrates that Cj1416 is fully capable of using L-glutamine phosphate (2) to displace pyrophosphate from CTP.

To provide further spectroscopic support for the Cj1416-catalyzed formation of CDP-L-glutamine, the reaction products were analyzed by 31P NMR spectroscopy. In this experiment, Cj1416 was incubated with CTP, MgCl₂, L-glutamine phosphate (2), and inorganic pyrophosphatase until the reaction was quenched with EDTA. After an incubation period of 90 min, essentially all of the CTP and L-glutamine phosphate (2) were converted to products (Figure 3A). A new resonance is observed at 3.02 ppm for phosphate (from the hydrolysis of CDP-L-glutamine to L-glutamate and cytidine diphosphoramidate). The 31P NMR spectrum (Figure 3C) of the reaction mixture remains intact. Two other resonances that are consistent with CDP-L-glutamine (5) are observed at 1.19 ppm. On the basis of these results, it is clear that Cj1416 is fully capable of catalyzing the formation of CDP-L-glutamine from CTP and L-glutamine phosphate (2) and that Cj1417 catalyzes the hydrolysis of CDP-L-glutamine to L-glutamate and cytidine diphosphoramidate.

The remaining issue to address for the functional characterization of Cj1417 is whether this enzyme is capable of catalyzing the hydrolysis of L-glutamine phosphate to L-glutamate and phosphoramidate (2). Cj1417 was therefore incubated with L-glutamine phosphate (2) at pH 8.0 for 90 min. The 31P NMR spectrum (Figure 3C) of the reaction mixture demonstrated that ~93% of the original L-glutamine phosphate (2) remained intact. Two other resonances that are consistent with the presence of a small amount of phosphate (3.08 ppm, 1.2%) and phosphoramidate (1.21 ppm, 5.5%) are observed. The 31P NMR spectrum for chemically synthesized phosphoramidate (2) is shown in Figure 3D, where a resonance is observed at 1.19 ppm. On the basis of these results, it is clear that the preferred pathway for the synthesis of cytidine diphosphoramidate (4) is for Cj1416 to catalyze the displacement of pyrophosphate from CTP to form CDP-L-glutamine (5) and for Cj1417 to catalyze the hydrolysis of this intermediate to generate cytidine diphosphoramidate (4) as shown in Scheme 2C.

The kinetic constants for the catalytic activity of Cj1417 and Cj1416 were determined. At a fixed concentration of either 5.0 mM MgCTP or 2.0 mM L-glutamine phosphate (2), the rates of the reaction catalyzed by Cj1416 were determined at 25 °C and pH 8.0 by monitoring the formation of products via anion exchange chromatography at 255 nm. The observed kinetic constants using L-glutamine phosphate (2) as the variable substrate are as follows: $K_m = 120 \pm 30 \mu M$, $k_{cat} = 57 \pm 6 \text{ min}^{-1}$, and $k_{cat}/K_m = (4.8 \pm 1.3) \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$. The observed kinetic constants using MgCTP as the variable substrate are as follows: $K_m = 170 \pm 35 \mu M$, $k_{cat} = 57 \pm 6 \text{ min}^{-1}$, and $k_{cat}/K_m = (3.4 \pm 0.8) \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$.

Figure 2. 31P NMR spectra of nucleotide standards and enzyme-catalyzed reaction products formed in 100 mM HEPEs (pH 8.0) at 25 °C with an incubation time of 90 min before the reaction was quenched with 10 mM EDTA. (A) Control sample containing 5.0 mM CTP, 5.0 mM MgCl₂, and 6.0 mM L-glutamine phosphate. (B) Sample containing 5.0 mM CTP, 5.0 mM MgCl₂, 6.0 mM L-glutamine phosphate, 20 μM Cj1416, and 20 μM Cj1417. (C) Control sample of 5.0 mM CDP phosphoramidate.

Figure 3. 31P NMR spectra of nucleotide standards and enzyme-catalyzed reaction products formed in 100 mM HEPEs (pH 8.0) at 25 °C with an incubation time of 90 min before the reaction was quenched with 10 mM EDTA. (A) Sample containing 5.0 mM CTP, 5.0 mM MgCl₂, 5 units/mL pyrophosphatase, and 20 μM Cj1416. (B) Cj1417 (20 μM) was added to the reaction mixture shown in panel A and the mixture allowed to react for an additional 90 min. (C) Sample containing 20 μM Cj1417 and 5.0 mM glutamine phosphate. (D) Control sample of 5.0 mM phosphoramidate.

CDP-L-glutamine disappear and are replaced by two new pairs of doublets at −0.43 ppm (β-P) and −10.24 ppm (α-P) that can be assigned to cytidine diphosphoramidate (Figure 3B and Figure 2C). These experiments demonstrate that Cj1416 catalyzes the formation of CDP-L-glutamine from CTP and L-glutamine phosphate (2) and that Cj1417 catalyzes the hydrolysis of CDP-L-glutamine to L-glutamate and cytidine diphosphoramidate.
The kinetic constants for the hydrolysis of CDP-L-glutamine (5) catalyzed by Cj1417 were determined at 25 °C and pH 8.0 using a glutamate dehydrogenase coupled assay that monitors the formation of NADH at 340 nm. The kinetic constants were determined to be as follows: $k_{cat} = 28 \pm 3 \mu M$, $k_{cat}/K_m = 34 \pm 1.2 \text{ min}^{-1}$, and $k_{cat}/K_m = (1.2 \pm 0.2) \times 10^6 \text{ M}^{-1} \text{ min}^{-1}$. In an effort to determine the upper limit of the rate constant for the hydrolysis of L-glutamine phosphate (2) by Cj1417, 10 mM L-glutamine phosphate (2) was incubated with 20 μM Cj1417, and the reaction was monitored by $^{31}$P NMR for 13 h. From this experiment, an upper limit of 1.6 h$^{-1}$ was obtained for the hydrolysis of l-glutamine phosphate by Cj1417. 

Previously, we have demonstrated that the first step in the biosynthesis of the MeOPN modification to the CPS of C. jejuni is catalyzed by Cj1418, where ATP is utilized to phosphorylate the amide nitrogen of l-glutamine. Here we have shown that Cj1416 catalyzes the displacement of pyrophosphate from MgCTP by L-glutamine phosphate (2), yielding CDP-L-glutamine (5). We have also established that the catalytic function of Cj1417 is to hydrolyze CDP-L-glutamine to l-glutamate and cytidine diphosphoramide (4). This investigation has thus unveiled the identities of two new nucleoside diphosphoramide derivatives that are involved in the biosynthesis of MeOPN. It is likely that cytidine diphosphoramide (4) will be subsequently phosphorylated at the hydroxyl group attached to C3 of the ribose ring prior to transfer of the phosphoramidate group to various carbohydrates of the CPS. On the basis of sequence similarity network analysis of the enzymes of unknown function contained within C. jejuni, we predict that Cj1415 will catalyze this reaction. Cj1415 is a member of cog0529, and the closest functionally characterized enzyme is CysC, an adenylyl-sulfate kinase, from E. coli (26% identity), an enzyme that catalyzes the ATP-dependent phosphorylation of the 3'-hydroxyl of adenylyl sulfate. The unique biosynthetic pathway for the assembly of the phosphoramidate functionality found in the CPS of C. jejuni offers many opportunities for the development of potent inhibitors that may ultimately be useful in the therapeutic control of this pathogenic organism.

**ACKNOWLEDGMENTS**

We thank Professor C. Szymanski and Mr. C. Wenzel for the plasmids that were used to express Cj1417 and Cj1416.

**REFERENCES**